Dr. da Costa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Furlong
Furlong, PA 18925Phone+1 267-406-2485
Summary
- US licensed and board-certified physician with over 20 years' experience in clinical medicine and over 15 years total of clinical and basic science research experience, including phase I-IV clinical development, medical affairs, health economics & outcomes research, regulatory affairs, and strategic leadership of clinical development teams. Expertise spans vaccine and small molecule clinical research and development, including efficacy, safety, and effectiveness studies for prophylactic pediatric vaccines, as well as expertise in strategic development planning in therapeutic vaccinology, including monoclonal antibody-based active and passive immunotherapy. Therapeutic area experience includes vaccines, infectious diseases, neuroscience, hematology, organ transplantation, and immunology. Clinical experience includes internal medicine, infectious diseases, wound care/ esthetic and hyperbaric medicine. Fellow American College of Physicians, Fellow Infectious Disease Society of America. Certified Wound Specialist Physician. Dr. da Costa was appointed to the staff of the Harvard T.H. Chan School of Public Health in August 2023 as a Takemi International Health Fellow.
Education & Training
- Harvard School of Public HealthFellowship, 2023 - 2024
- Harvard Medical SchoolGlobal Health, Global Health Care Leaders Program, 2021 - 2022
- Wharton School, University of PennsylvaniaEntrepreneurial Acceleration Program, Executive education (Business), 2019 - 2019
- Auburn UniversityMBA, Physician's Executive MBA, 2001 - 2003
- Kirk Kerkorian School of Medicine at UNLVChief Residency, Internal Medicine, 1998 - 1999
- Kirk Kerkorian School of Medicine at UNLVResidency, Internal Medicine, 1996 - 1998
- London School of Hygiene & Tropical MedicinePhD, Immunology (Infectious Diseases), 1987 - 1991
- London School of Hygiene & Tropical MedicineMSc., Clinical Tropical Medicine, 1985 - 1986
- University of Zambia, School of MedClass of 1983
Certifications & Licensure
- FL State Medical License 2018 - 2026
- PA State Medical License 2007 - 2024
- NC State Medical License 2011 - 2016
- VA State Medical License 2000 - 2016
- CA State Medical License 2011 - 2014
- American Board of Internal Medicine Internal Medicine
- AAPLCertification in Medical Management (CPE)
- American Board of Wound ManagementCertified Wound Specialist Physician
Awards, Honors, & Recognition
- Fellow American College of Physicians
- Fellow Infectious Disease Society of America
- Best Internal Medicine Resident, Ambulatory Clinic University of Nevada School of Medicine, 1998-1999
- Join now to see all
Clinical Trials
- Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease Start of enrollment: 2007 May 01
- Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease Start of enrollment: 2007 Nov 01
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Start of enrollment: 2007 Nov 20
- Join now to see all
Publications & Presentations
PubMed
- 440 citationsGuillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data.James J. Sejvar, Katrin S. Kohl, Jane Gidudu, Anthony A. Amato, Nandini Bakshi
Vaccine. 2011-01-10 - 42 citationsDiarrhea: Case definition and guidelines for collection, analysis, and presentation of immunization safety dataJane Gidudu, David A. Sack, M. Pina, Michael J. Hudson, Katrin S. Kohl
Vaccine. 2011-01-29 - 18 citationsSafety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 MonthsMaurice A. Mufson, Clemente Diaz, Michael Leonardi, Christopher J. Harrison, Stanley E. Grogg
Journal of the Pediatric Infectious Diseases Society. 2015-12-01
Journal Articles
- Perspectives on Advancement and Development of Tuberculosis VaccinesChristopher da Costa, Christine S. Benn, Thomas Nyirenda, Evans Mpabalwani, Harleen M.S. Grewal, Rizwan Ahmed, Nathan Kapata, Peter S. Nyasulu, Markus Maeurer, David S..., International Journal of Infectious DIseases, 2/25/2024
- End of the Bedaquiline patent – a crucial development for moving forward affordable drugs, diagnostics, and vaccines for infectious diseases in low- and middle-income ...Eskild Petersen, David S. Hui, Jean B. Nachega, Francine Ntoumi, Delia Goletti, Eleni Aklillu, Avinash Sharma, Thomas Nyirenda, Dorothy Yeboah-Manu, Giovanni Satta, Ch..., International Journal of Infectious DIseases, 4/6/2023
- SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b StudyJohn Kokai-Kun, PhD, Tracey Roberts, BSN, Olivia Coughlin, PhD, Heidi Whalen, MHS, Charles Le, PhD, Christopher Da Costa, MD, PhD and Joseph Sliman, MD, PhD, Open Forum Infect Dis. 2017 Fall; 4(Suppl 1): S12. Published online 2017 Oct 4. doi: 10.1093/ofid/ofx162.029 PMCID: PMC5631845, 2017
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Immunogenicity of GlaxoSmithKline Biologicals, MMR Vaccine vs M-M-R® II, when Co-administered with Hepatitis A, Varicella and Pneumococcal Conjugate Vaccines to Toddle...da Costa, C, https://idsa.confex.com/idsa/2011/webprogram/Paper31923.html, 10/21/2011
- Efficacy of Two-dose MMRV and One-dose Varicella Vaccination in Children Aged 12-22 Months in 10 European Countriesda Costa, C, http://www.kenes.com/espid2010/posters/Abstract619.htm, 5/4/2010
- Immunogenicity of one dose of Varicella vaccine and two doses of MMRV vaccine.da Costa, C, http://www.kenes.com/espid2010/posters/Abstract558.htm, 5/4/2010
- Join now to see all
Lectures
- Strengthening local supply chains, manufacturing & innovation for novel vaccinesUniversity of Miami Global Health Program - 2/27/2024
- CEPI: New vaccines for a safer worldMassachussetts General Hospital/Harvard University - 10/2/2023
- COVID-19 – New Variants and Long COVIDNational Medical Assocociation- Task Force on Vaccines and Therpeutics - 2/4/2023
- Join now to see all
Other
- Making the transition from clinical medicine to the pharmaceutical industry – Perspectives from real world experiences of a physicianChristopher da Costa
http://www.rxeconsult.com/healthcare-articles/From-Clinical-Medicine-to-Pharmaceutical-Industry---Physician-Experience-274/
2/3/2013 - From Physician Practice to Pharmaceutical Industry CareerChristopher da Costa
http://www.rxeconsult.com/healthcare-articles/From-Physician-Practice-to-Pharmaceutical-Industry-Career-273/
2/1/2013
Authored Content
- Advances in Development of New Tuberculosis VaccinesMay 2023
Press Mentions
- Mentoring the Future of Health: An Evening with Dr. Chris Da Costa & Dr. Monica SoniOctober 18th, 2016
- COVID-19 Alumni Stories: Christopher da CostaJuly 19th, 2020
Grant Support
- Research Initiative Fund GrantUniversity of Wales College of Medicine1993–1995
- Beit Memorial Medical Research Fellowship GrantBeit Trust1987–1991
Research History
- Physician Reviewer (Consultant)Physician Reviewer for FDA Biologics Safety and Effectiveness Program for Vaccine and Blood Transfusion Products2019 - Present
- Consultant, Vedanta BiosciencesMIcrobiome Therapeutics for the prevention of recurrent Clostridium difficile Infection, using Bacterial Consortia2018 - 2019
- Consultant, Intarcia Therapeutics, Boston, MAClinical Development and Pharmacovigilance for a Drug-Device combination product for use in Glycemic Control in Diabetes Mellitus.2018 - 2019
- Vice President of Clinical Development, Synthetic BiologicsClinical research and development of a first-in-class agent for the prevention of Clostridium difficile infection, and of a novel therapy for Irritable Bowel Syndrome with constipation (IBS-C).2017 - 2017
- Global Medical Director, Asahi Kasei Pharma AmericaClinical development of recombinant thrombomodulin as a novel therapy for patients with sepsis, and for the prevention of early allograft dysfunction in liver transplant patients.2015 - 2017
- Director of Clinical Development, Tuberculosis Vaccines, AerasClinical research and development of TB vaccines.2014 - 2015
- Senior Medical Director, Pfizer Infectious DiseasesPhase IV clinical research on antibiotics Vancomycin and Linezolid.2011 - 2013
- Compound Development Team Leader, Janssen Alzheimer Immunotherapy R&D, LLCClinical research on active and passive Immunotherapy for Alzheimer's disease.2010 - 2011
- Director, Clinical Development and Medical Affairs, GlaxoSmithKline VaccinesClinical research and development of MMR and Varicella vaccines.2006 - 2010
- Associate Director, Worldwide Regulatory Affairs, Merck and Co.Clinical research on Measles, Mumps, Rubella and Varicella vaccines.2005 - 2006
- Clinical Lecturer and Research Fellow in Tropical MedicineResearch on immunology of tuberculosis in the context of HIV infection, at the London School of Hygiene & Tropical Medicine.1987 - 1991
Professional Memberships
- Certified Physician Executive (CPE)
- Fellow
- Fellow
- American Board of Wound ManagementCertified Wound Specialist Physician
- Pennsylvania Medical SocietyMember
- Bucks County Medical SocietyMember
- Florida Medical AssociationMember
Other Languages
- French, Creole
External Links
- Christopher da Costa, MD, PhD, FACP, FIDSAhttps://www.linkedin.com/in/christopher-t-k-abs/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: